We have examined whether the secretion of erythropoietin (Epo) from genetically modified cells could represent an alternative to repeated injections of the recombinant hormone for treating chronic anemias responsive to Epo. Primary mouse skin fibroblasts were transduced with a retroviral vector in which the murine Epo cDNA is expressed under the control of the murine phosphoglycerate kinase promoter. "Neo-organs" containing the genetically modified fibroblasts embedded into collagen lattices were implanted into the peritoneal cavity of mice. Increased hematocrit (>80%o) and elevated serum Epo concentration (ranging from 60 to 408 milliunits/ml) were observed in recipient animals over a 10-month observation period. Hematocrit values measured in recipient mice varied according to the number of implanted Epo-secreting fibroblasts (ranging from 2.5 to 20 x 106). The implantation of neo-organs containing Eposecreting fibroblasts appeared, therefore, as a convenient method to achieve permanent in vivo delivery of the hormone. We estimated that the biological efficacy of the approach may be relevant for the treatment of human hemoglobinopathies.
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Erythropoietin (Epo) is the glycoprotein hormone regulating erythropoiesis in mammals (1, 2) . It -is secreted mainly by kidney peritubular cells (3) in response to hypoxia and binds a specific cell surface receptor on late erythroid precursors, thus promoting their proliferation and terminal differentiation into erythrocytes.
Recombinant human Epo (rHuEpo) is widely used as a replacement therapy for anemic patients in whom a normal erythropoiesis can be stimulated (4, 5) . This is the case of chronic renal failure, in which anemia results from a destruction of Epo-secreting cells (6) and in chronic inflammatory (e.g., rheumatoid arthritis and cancers) or infectious (e.g., AIDS with or without 3Y-azido-3'-deoxythymidine therapy) diseases.
Epo therapy has also been proposed for treatment of hemoglobinopathies in which /3-globin chain synthesis is affected (4, 5) . The rationale for this approach is to stimulate the synthesis of y-globin chains. Although this molecule does not significantly participate in the synthesis of adult hemoglobin (HbA; a2-P32), its expression could compensate a /3-globin defect by the production of fetal hemoglobin (HbF; a2-y2). A therapeutic effect of repeated injections of high doses of rHuEpo associated with hydroxyurea has been demonstrated in patients with sickle cell disease. Treatment resulted in increased HbF synthesis, decreased polymerization of abnormal hemoglobin (HbS), and improvement of rheologic properties of erythrocytes (7) . In the /3-thalassemic mouse, repeated injections of high doses of rHuEpo (8) , as well as the
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transplantation of bone marrow cells engineered to secrete rHuEpo by retrovirus-mediated gene transfer (9) , were shown to stimulate the synthesis of 3-minor globin chains (the mouse equivalent of human y-globin chains), leading to improvement of the /3-thalassemic phenotype of erythrocytes and to increased hematocrit (Hct). High doses of rHuEpo were also administered to human patients with thalassemia intermedia, in whom they improved anemia (10, 11) . However, the considerable cost of a permanent Epo treatment at high doses precludes administration in large populations of patients with hemoglobinopathy.
An alternative approach for a permanent delivery of high doses of rHuEpo would consist of implanting autologous cells genetically modified to secrete the hormone into the serum. Skin fibroblasts are especially suitable for that purpose. They can be grown in culture, transduced with a retroviral vector, and grafted back to the donor after inclusion into collagen lattices. We have shown that the intraperitoneal implantation of collagen lattices containing genetically modified cells and synthetic fibers coated with an angiogenic factor leads to the development of vascularized "neo-organs" from which soluble proteins can be delivered into the serum. This approach was used with success to deliver ,B-glucuronidase in mice deficient for this enzyme (12) .
In the present study, the murine Epo cDNA has been inserted into a retroviral vector where it is expressed from the mouse phosphoglycerate kinase gene (PGK-1) promoter. We have previously shown that, in contrast with other promoters (13, 14) , this housekeeping gene promoter is not shut off after the in vivo engraftment of fibroblasts (12) . Mouse skin fibroblasts were transduced with this vector, and neo-organs containing Epo-secreting cells were implanted into normal mice. We observed a rapid and persistent increase of the Hct and of Epo plasma levels, which could be modulated according to the number of implanted cells. cycles of PCR amplification with synthetic oligodeoxynucleotide primers complementary to the 5' region (5'-GGT-TCGTCGACGGAGCTAGGCGCGGAGATG-3') and the 3' region (5'-GGTTCGGTACCACGTGGCAGCAGCATGTC-3') of the murine Epo gene coding sequence (17) . The amplified product was inserted into a pBSIIKS plasmid (Stratagene) and sequenced. A Kpn I/Sal I fragment containing the murine cDNA sequence was BamHI linked and inserted into a U3-deleted Moloney-based retroviral vector downstream of the internal mouse PGK-1 promoter (Fig. 1A) (15) . The construction was transfected into 4ICRE ecotropic packaging cells (18) along with pSV2-neo, and a helper-free high-titer producer clone was isolated (EPO-16). Southern blot analysis revealed that incubation for 2 hr at 37°C of NIH 3T3 cells with filtered (0.45 ,lm) 24-hr supernatant led to the transfer of two or three unrearranged proviral copies in infected cells (Fig. 1 B,  lane 4) . As expected for a U3-deleted self-inactivating retroviral vector (19) , Northern blot analysis showed that transcription of the Epo cDNA switched from the long terminal repeat (LTR) promoter in vector-producing cells (Fig. 1 C, plantation (P < 0.0005). This level was maintained throughout the 6 months following implantation (Table 1 and Fig. 2) . Although a progressive decrease was observed thereafter in three mice not sacrificed at this time (mice 1, 3, and 5), Hct values were still significantly elevated at 10 months (69%, 67%, and 56%, respectively). Plasma Epo levels measured by ELISA ranged from 60 to 408 milliunits/ml (means: 189 ± 102 milliunits/ml at day 56 and 275.2 ± 118.2 milliunits/ml at day 126) and were therefore significantly higher than preimplantation values (<20 milliunits/ml; P < 0.01) ( Proc. NatL Acad ScL USA 92 (1995) eight DBA/2J mice (mice 7-14 in Table 1 ). Hct increased in all animals as early as 1 week after implantation and plateaued in a dose-dependent manner (Table 1 and Fig. 3) . While a plateau value of 52% was reached at 2 weeks in animals carrying 2.5 x 106 Epo-secreting cells, Hct went up to 64% at 3 weeks when 5 x 106 cells were implanted, to 74% at 6 weeks with 10 x 106 cells, and to 81% at 8 weeks with 20 x 106 cells (Fig. 3) . Consistent with our previous observations, the Hct plateau value was maintained for up to 20 weeks in mouse 8 carrying 20 x 106 Epo-secreting cells. In contrast, in animals carrying 2.5 x 106, 5 x 106, and to a lesser extent in animals carrying 10 x 106 Epo-secreting cells, a progressive decline of Hct values occurred within the 10 weeks after implantation. Plasma Epo levels measured 4 weeks postimplantation were significantly elevated compared to initial values (P < 0.005). However, because of large individual variations, these values could not be correlated to the number of Epo-secreting cells (Table 1 ). These data suggested that Epo plasma levels and Hct depended on the number of genetically modified skin fibroblasts introduced in neo-organs.
MATERIALS AND METHODS
On day 80 after implantation, mice 2, 7, and 9 were sacrificed. Except for the presence of polycythemia and enlarged spleen, the autopsy was normal. Histological sections performed on the spleen of mouse 9 showed a normal structure with an increased proportion of normal erythroid elements. Neo-organs were removed, a fraction was used for DNA extraction, and single cell suspensions were plated in tissue culture (_ 106 cells were recovered from each neoorgan). Hybridization of a Southern blot with an Epo-specific probe revealed the presence of the EPO-16 vector genome in neo-organ DNA, indicating that genetically modified cells survived i"n vivo for at least 12 weeks. The average vector copy number per cell at the time of sacrifice was 0.5 for mouse 2 ( Fig. 1 B, lane 6 Epo-secreting cells in neo-organs. According to these data, we estimated that Epo-secreting cells represented between 12% (from Southern blot analysis) and 40% (from Epo secretion in cell cultures) of the total cell population present in neo-organs 80 days after implantation.
To search for genetically modified cells that could have migrated from neo-organs to distant tissues, vector-specific PCR was performed on DNA extracted from liver, lung, spleen, kidney, and heart of mice 2 and 9. Whereas a control amplification of a myogenin sequence gave a signal in all DNAs, the 640-bp vector-specific band was absent. It was therefore unlikely that significant numbers of transduced fibroblasts migrated to distant organs, suggesting that the sustained elevation of Hct and serum Epo levels was a direct consequence of the maintenance of Epo-secreting cells in neo-organs.
DISCUSSION
The clinical applications of Epo are rapidly expanding. Lifelong treatment with very high doses is now under evaluation for hemoglobinopathies (7, 10, 11) . These indications make a search for methods allowing a permanent in vivo delivery of the hormone worthwhile.
The present study shows that the intraperitoneal implantation of neo-organs containing -autologous skin fibroblasts engineered to secrete murine Epo induced a permanent polycythemia due to increased circulating Epo levels in recipient mice. This sustained in vivo delivery of the hormone was possible because of the stability of the mesenchymal tissue in neo-organs. We have previously observed that inflammatory reaction is minimal in neo-organs and that a rich network of capillary vessels irrigates the cells. Skin fibroblasts enter in a resting state after inclusion into collagen lattice and do not divide after implantation into the animal. We estimated that after 4 months in vivo, at a time when neo-organs have been intensively colonized by host cells, Epo-secreting cells represented between "12% (as estimated from Southern blot analysis) and "40% (as estimated from Epo secretion after 22 Weeks post-implantation FIG. 3. Long-term monitoring of the Hct in mice implanted with various numbers of Epo-secreting fibroblasts. Six-week-old DBA/2J mice (mice [7] [8] [9] [10] [11] [12] [13] [14] were implanted with collagen lattices containing mixtures of transduced and uninfected fibroblasts to a total of 2 x 107 cells. Mice 7 and 8 (-) were implanted with 20 x 106, mice 9 and 10 (El) were implanted with 10 x 106, mice 11 and 12 (-) were implanted with 5 x 106, and mice 13 and 14 (0) were implanted with 2.5 x 106 transduced fibroblasts. Mice 12, 14, and 10 were found dead 10, 11, and 14 weeks, respectively, after implantation. Mice 7 and 9 were sacrificed 12 weeks after transplantation, as indicated by an asterisk. Ti and T2 refer to data shown in Table 1 . Hct values in untreated mice are between dashed lines (45% ± 1.5%).
replating of cells extracted from neo-organs) of the total neo-organ cell population. Considering the stability of Hct values for up to 6 months in mice 1-6, one can consider that the total number of Epo-secreting cells was stable during that period and that the genetically modified population was diluted with colonizing host cells. Nevertheless, a progressive decline of Hct was observed between 6 and 10 months in mice 1, 3, and 5 and before 10 weeks in mice 9-14. It is therefore possible that the number of Epo-secreting cells slowly decreased over time, suggesting that the environment may not be optimal for the self-renewal of transduced fibroblasts. It is less likely, but not impossible, that the decrease of Epo secretion resulted from a late and progressive shutoff of the PGK-1 promoter in a fraction of the cells. In mice that received 2 x 107 genetically modified fibroblasts, Hct values reached 81.8% ± 1.5% at 8 weeks postimplantation. Epo serum levels were significantly higher in treated mice compared to controls, but, in contrast to Hct values, they showed large variations from one animal to the other. This may reflect interindividual differences in Epo turnover. The daily delivery of Epo in treated animals can be roughly estimated according to the amount of hormone secreted in vitro before implantation. Although a comparison of the biological effect of rMuEpo delivered from neo-organs and repeated injections of rHuEpo may not be accurate, it is noticeable that equivalent Hct values (60-65%) were measured both in animals bearing neo-organs containing 5 x 106 cells (supposed to deliver 45 units of rMuEpo per 24 hr) and in animals injected daily with 50 units of rHuEpo 5 days a week (8) . The estimated in vivo Epo secretion from neo-organs in mice would therefore be in the range of 1000 units/kg per day. Doses of rHuEpo that were shown to be beneficial in patients with hemoglobinopathies are 500-1500 units/kg daily three times a week (10, 11) . According to our estimation, it is likely that the implantation of Epo-secreting skin fibroblasts might therefore be relevant for the treatment of these diseases in humans. As estimated on the basis of the relative body weight, therapeutic effect could be obtained in patients by implanting 1010 genetically modified autologous cells, while 109 cells would be enough for a correction of the anemia associated with chronic renal failure. We have recently implanted neo-organs in the omentum of dogs that contained up to 6 x 109 genetically modified skin fibroblasts and that were kept functional for over a year (P.M., J.M.H., and O.D., unpublished work). In view of future human applications of this technique, human fibroblasts obtained from skin biopsies were transduced with a retroviral vector, amplified to a similar extent, and used to prepare neo-organs in vitro.
Both the long-term survival of recipient mice and the histological aspect of neo-organs indicated that no tumoral proliferation of implanted fibroblasts had occurred in these animals. An important issue in view of clinical applications is the control of Epo delivery in order to avoid the risks associated with polycythemia in treated patients. Since the Hct varied according to the number of implanted Epo-secreting fibroblasts, one possibility would be to initially implant low numbers of engineered fibroblasts and then work up to the adequate number for each patient. The process could be reversible, as we have shown in a previous study that neoorgans can be surgically removed if necessary (12) . However, a tighter in vivo regulation of Epo delivery would be achieved by using retroviral vectors containing inducible promoters.
